Loading…
Loading…
ISRG does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for ISRG and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for ISRG and 80,000+ other tickers.
See exactly how ISRG's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ISRG and 80,000+ other tickers.
Intuitive Surgical, Inc. is a leading medical technology firm dedicated to advancing patient care by developing, producing, and commercializing sophisticated tools. These innovations empower medical professionals to deliver superior, accessible, and less-invasive treatment options to patients both within the United States and across international markets. Its flagship offering, the da Vinci Surgical System, facilitates intricate operations through a minimally disruptive approach. Expanding beyond surgical applications, the company also provides the Ion endoluminal system, designed for…
Ark Invest bought into some market laggards on Wednesday.
Intuitive Surgical NASDAQ: ISRG shocked the market by reporting not one but two margin impairments in its Q3 results, but investors shouldn't misread this.
Intuitive Surgical (NASDAQ: ISRG - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at BTIG Research in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $454.00 price target on the medical equipment provider's stock. BTIG Research's price target would suggest a potential upside of 6.05%
Intuitive Surgical (ISRG) and Elevance Health (ELV) delivered impressive Q3 earnings beats, making both healthcare stocks worth considering as their growth outlooks improve.
Intuitive Surgical's Q3 earnings call highlights instrument price cuts to boost robotic surgery adoption, higher 2026 margins and slowing U.S. procedure growth.